Novartis's Glivec nears wider EU approval

EU close to giving green light for Novartis's glivec treatment Keystone

A European Union advisory panel has recommended Novartis's glivec drug for treating a rare form of gut cancer.

This content was published on February 22, 2002 - 09:52

The Swiss healthcare giant said on Friday that this latest move by the EU sets the stage for formal approval of the drug by mid-year.

The Committee for Proprietary Medical Products (CPMP) suggested approval of glivec for treating inoperable or metastatic malignant gastrointestinal tumours, which affect around 12,000 new patients every year.

The EU normally approves products within four months after such a positive opinion.

Actelion success

The CPMP also recommended Swiss biotech company Actelion's tracleer for treating pulmonary arterial hypertension, a chronic and life-threatening disorder that disrupts heart and lung functioning.

The drug is already approved in North America for treating the disease.

swissinfo with agencies

This article was automatically imported from our old content management system. If you see any display errors, please let us know:

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story

Change your password

Do you really want to delete your profile?